
Lifecore Biomedical, Inc.: updates and filings
Price
$6.39
November 20, 2026Market cap $239M
What Ploutos Investor adds for Lifecore Biomedical
Part of Ploutos Investor, €9.99 a month
- The full history: 16 fiscal years, from FY2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
- The latest annual figures the company filed are for 2025, more than a year ago. Newer ones may be late.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 4, 2026next Feb 5, 2027
A rough estimate from when it has reported before, which has varied. The company announces the date itself.
November 2026
October 2026
September 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 13, 2026Merger meeting proxy statementFormDEFM14A
- Nov 5, 2026Additional annual meeting materialFormDEFA14A
- Nov 5, 2026Other material eventsForm8-K
- Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 4, 2026Results of operationsForm8-K
- Oct 30, 2026FilingFormPREM14A
- Oct 20, 2026Other material eventsForm8-K
- Sep 29, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Sep 29, 2026Material agreement enteredForm8-K
- Sep 28, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Sep 28, 2026Additional annual meeting materialFormDEFA14A
- Sep 28, 2026Material agreement entered, Regulation FD disclosureForm8-K
- Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 5, 2026Results of operations, Regulation FD disclosureForm8-K
- Jul 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 2, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jul 2, 2026Regulation FD disclosureForm8-K
- Jul 2, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jun 5, 2026Officer or director change, shareholder voteForm8-K
- May 6, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 6, 2026Results of operations, Regulation FD disclosureForm8-K
- Apr 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 24, 2026Annual meeting proxy statementFormDEF 14A
- Mar 16, 2026Filingfor the period to Dec 31, 2025Form10-KT
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 13, 2026 | DEFM14A | Merger meeting proxy statement | Document |
| Nov 5, 2026 | DEFA14A | Additional annual meeting material | Document |
| Nov 5, 2026 | 8-K | Other material events | Document |
| Nov 4, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 4, 2026 | 8-K | Results of operations | Document |
| Oct 30, 2026 | PREM14A | Filing | Document |
| Oct 20, 2026 | 8-K | Other material events | Document |
| Sep 29, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Sep 29, 2026 | 8-K | Material agreement entered | Document |
| Sep 28, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Sep 28, 2026 | DEFA14A | Additional annual meeting material | Document |
| Sep 28, 2026 | 8-K | Material agreement entered, Regulation FD disclosure | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 5, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Jul 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 2, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jul 2, 2026 | 8-K | Regulation FD disclosure | Document |
| Jul 2, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jun 5, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 6, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 6, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Apr 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 24, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 16, 2026 | 10-KT | Filingfor the period to Dec 31, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 13, 1996.
The full analysis
What do Lifecore Biomedical's filings show?
The filings are where every one of Lifecore Biomedical's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.